We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 07, 2020

Immune Checkpoint Inhibitors in Patients With MSI-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden

The Oncologist

 

Additional Info

The Oncologist
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
Oncologist 2020 May 05;[EPub Ahead of Print], F Pietrantonio, F Loupakis, G Randon, A Raimondi, M Salati, D Trapani, F Pagani, I Depetris, G Maddalena, F Morano, S Corallo, M Prisciandaro, F Corti, V Guarini, A Bocconi, A Marra, C Belli, A Spallanzani, M Fassan, S Lonardi, G Curigliano, G Fucà, M Di Bartolomeo, F de Braud

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading